To evaluate the efficacy of limus-coated balloons (Limus-DCB) compared with paclitaxel-coated balloons (PCB) in the treatment of coronary artery disease.
Approach:
Literature Search: A systematic search was conducted in PubMed, Embase, Cochrane Library, and Web of Science for randomized controlled trials (RCTs) comparing Limus-DCB with PCB from inception to June 2026.
Data Extraction: Two reviewers independently screened the literature, extracted data, and assessed the risk of bias of the included studies.
Meta-Analysis: Meta-analysis was performed using RevMan 5.4.1 software.
Key Findings:
The Limus-DCB group showed marginally greater in-segment late lumen loss (LLL) (MD = 0.10, 95% CI 0.00–0.19, P = 0.04).
The Limus-DCB group had marginally smaller in-lesion minimal lumen diameter (MLD) (MD = -0.10, 95% CI -0.19 to 0.00, P = 0.04).
No significant differences were found between Limus-DCB and PCB in in-lesion LLL, late lumen enlargement (LLE), binary restenosis rate, target lesion failure (TLF), or major adverse cardiovascular events (MACE).
Interpretation:
Limitations:
Limitations in the quantity and quality of the included studies.
Need for verification of findings by more high-quality research.
